Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fusion protein of IL-2 mutant and antibody and application of fusion protein

A fusion protein, mutant technology, applied in the field of biotechnology and antibody engineering, can solve problems such as low reaction rate

Active Publication Date: 2019-09-20
INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
View PDF4 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the response rate of single-drug patients is low

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion protein of IL-2 mutant and antibody and application of fusion protein
  • Fusion protein of IL-2 mutant and antibody and application of fusion protein
  • Fusion protein of IL-2 mutant and antibody and application of fusion protein

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0142] Example 1: Treg cells inhibit WT IL-2 from exerting its biological function

[0143] Considering the toxic and side effects of clinical use of large doses of IL-2, we fused IL-2 with the Fc of human antibody IgG1, and expressed and purified it using a mammalian suspension cell expression system. Low doses of Free IL-2 could not control the growth of tumors. When B16F10 tumor-bearing mice were treated with the same dose of IL2-Fc, the tumor growth of mice was relatively controlled but still showed an upward trend ( figure 1 A). This result indicated that the wild-type IL-2 also played the function of suppressing the immune response in the process of functioning. Through detection, it was found that there were more Tregs in tumor tissue than in lymphoid organs ( figure 1 B). This suggests the necessity of reducing IL-2 binding and inducing activation of proliferating Tregs.

Embodiment 2

[0144] Example 2: sumIL-2 enhances the binding and expansion of activated CD8 T cells, reduces the binding and expansion of Treg cells

[0145] We introduced the above six mutation sites in IL-2. We expressed and purified the fusion Fc forms of WTIL-2-Fc and sumIL-2-Fc, and tested the ability of the two fusion proteins to bind to the receptor and bind to effector cells in vitro.

[0146] To characterize the ability of WT IL-2 and sumIL-2 to bind different T cell subsets, we compared the differences in T cell binding of IL-2 fusion proteins by in vitro cell binding assays. In the same spleen cells,

[0147] (1) The ability of WT IL-2 to bind Treg cells is higher than that of memory CD8+ T cells ( figure 1 C);

[0148] (2) On the contrary, sumIL-2 is more inclined to bind memory CD8 + T cells but not Treg cells ( figure 1 C).

[0149] These in vitro experiments demonstrate that sumIL-2 is designed to activate memory CD8+ T cells rather than Treg cells.

[0150] In order...

Embodiment 3

[0151] Example 3: SumIL-2 has stronger anti-tumor activity than WT IL-2

[0152] In order to compare the anti-tumor function of the constructed IL-2 mutant and wild-type IL-2 in vivo, we used the mouse melanoma model to evaluate. SumIL-2 showed a tendency to bind activated CD8+ T cells in in vitro cell binding experiments, so the changes in T cells in tumors after treatment with sumIL-2 or WT IL-2 were first detected.

[0153] The same dose (5 μg) of sumIL-2-Fc and WT IL-2-Fc fusion protein was injected into the tumor, and the change of the cell ratio in the mouse tumor was detected by flow cytometry 3 days later. CTL is a very important factor associated with tumor regression, we found that sumIL-2 can increase the ratio of CD8 / CD4 ( figure 1 F), and can increase the ratio of CD8 / Treg ( figure 1 G), which indicates that mutant IL-2 can indeed expand more CD8+ T cells in the tumor. With such strong evidence, we further evaluated the tumor therapeutic effects of sumIL-2 an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a fusion protein of an IL-2 mutant and an antibody and application of the fusion protein. The fusion protein is a heterotrimeric protein composed of an IL-2 mutant (sumIL-2) and a tumor treatment antibody, the structure of the heterotrimeric protein is similar to that of the antibody, and the structural diagram is shown in figure 2A. Three monomers of the heterotrimeric protein are respectively as follows: (1) first monomer: fusion protein formed by fusing an IL-2 mutant (sumIL-2) and an immunoglobulin Fc fragment sequentially comprises sumIL-2 and an immunoglobulin Fc region from the N end to the C end; (2) second monomer: a single heavy chain of a tumor treatment antibody sequentially comprises a heavy chain variable region VH, a heavy chain CH region and an immunoglobulin Fc region of the antibody from the N end to the C end, and an immunoglobulin Fc region contained in the second monomer can be paired with an immunoglobulin Fc fragment of the first monomer to form a heterodimer; and (3) third monomer: a single light chain (comprising a VL region and a CL region) of the tumor treatment antibody, wherein the CL region contained in the third monomer can be paired with CH of the second monomer to form a heterodimer with a half-antibody structure; and the tumor treatment antibody is an antibody targeting a high-expression membrane protein on the surface of a tumor cell.

Description

technical field [0001] The invention belongs to the technical fields of biotechnology and antibody engineering, and specifically relates to a fusion protein of an IL-2 mutant and an antibody and its application. Background technique [0002] Interleukin-2 (IL-2), a T-cell growth factor induced by antigen stimulation, is a pleiotropic cytokine that plays a key role in the immune response 1,2 . A potent inducer of cytotoxic T cells and NK cells, IL-2 was one of the first FDA-approved immunotherapies for metastatic melanoma and renal cell carcinoma 3,4 . Unfortunately, due to short in vivo half-life, therapeutic doses and severe toxicity 5 And other issues, IL-2 immunotherapy has not been widely used. [0003] IL2 induces the proliferation of regulatory T cells (Tregs) by binding to IL-2 receptor alpha (IL-2Ra), which is preferentially expressed on Tregs 6,7,8,9,10 . IL-2 depletion by Treg cells has been shown to reduce IL-2-induced antitumor immunity, suggesting that Tre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00A61K38/20A61K47/68A61P35/00
CPCC07K14/55A61P35/00C07K2319/30C07K2319/33A61K38/00
Inventor 彭华孙志辰其他发明人请求不公开姓名
Owner INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com